INVIVYD, INC. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
INVIVYD, INC. (IVVD) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $12.70 million as of 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2025-11-06
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $12.70M.
- 2025-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $14.80M.
- 2025-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $19.00M.
- 2024-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $21.50M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2025-09-30 | $12.70M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $14.80M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $19.00M 10-Q · filed 2025-05-15 |
| 2024-09-30 | $21.50M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $28.40M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $40.20M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $0.00 10-K · filed 2024-03-28 |
| 2023-09-30 | $37.30M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $42.70M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $53.80M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $62.00M 8-K · filed 2024-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |